EGF Receptor (D38B1) XP ® Rabbit mAb 4267S from Cell Signaling Technology

Product Specs
ItemEGF Receptor (D38B1) XP ® Rabbit mAb
CompanyCell Signaling Technology
Price $386.00 Inquire
Catalog Number4267S
Quantity100 µl
ApplicationsW, W-S, IP, IHC-Bond, IHC-P, IF-IC, FC-FP
ReactivityH, M, Mk
TargetEGFR
HostRabbit
NCBI Gene AliasesERBB, ERBB1, ERRP, HER1, NISBD2, PIG61, mENA
ClonalityMonoclonal
NCBI Full Gene Nameepidermal growth factor receptor

Questions and Answers

What types of cancer models have utilized this antibody for research purposes?

The EGF Receptor (D38B1) XP Rabbit mAb has been shown to work in various cancer models, including non-small cell lung cancer, where it has been used to study the effects of EGFR mutations and the efficacy of EGFR-targeted therapies, such as in the context of acquired drug resistance to tyrosine kinase inhibitors like gefitinib and erlotinib (, ).

Can this antibody be used for immunohistochemistry, and if so, what has been observed in studies?

Yes, this antibody is suitable for immunohistochemistry. Studies have demonstrated its application in identifying EGFR expression levels in tumor samples, which is critical for understanding tumor biology and patient stratification in cancers such as oligodendroglioma and head and neck squamous cell carcinoma (, ).

How has this antibody contributed to understanding resistance mechanisms in cancer therapies?

The EGF Receptor (D38B1) XP Rabbit mAb has been utilized to investigate the mechanisms of resistance to EGFR-targeted therapies. For instance, it has been involved in studies that explore how mutations in the EGFR can lead to adaptive resistance, highlighting the importance of this receptor in therapeutic responses (, ).

What species can this antibody react with, and how does this influence its application in research?

This antibody is reactive with human, mouse, and non-human primate species. This broad reactivity allows researchers to apply it in various experimental models, including in vitro studies with human cell lines and in vivo studies using mouse models, facilitating translational research in cancer biology (, ).

Cell Signaling Technology

3 Trask Lane

Danvers, Massachusetts 01923

United States

Phone: 877-616-CELL
Phone: 978-867-2388
Fax: 866-432-6112
Fax: 978-867-2488

Company Profile

Website: http://www.cellsignal.com/

Website: Technical Support

(1) Tetraspanin CD82 shapes EGFR signaling outcomes through nanoscale receptor organizationJournal of Cell BiologyMay 4, 2026Sebastian Restrepo Restrepo Cruz, Michael J. Wester, Vernon S. Pankratz, Diane S. Lidke, Keith A. Lidke, Jennifer M. Gillettefollowing antibodies were used for western blots at a 1:1,000 dilution: Anti-EGFR (Clone D38B1, CST #4267), Anti-EGFR pY845 (Clone 12A3, SCBT # sc-57542), Anti-EGFR pY992 (ThermoFisher #44-786G), Anti-EGFR

(2) EGFR-Targeted Extracellular Vesicles Potentiate Doxorubicin-Induced Apoptosis and Tumor Suppression in Colorectal CancerInt J Mol SciApril 21, 2026Chan Mi Lee, Ji Won Choi, Do Sang Lee, Joo Won Moon, Jin Beom Cho, Jung Hoon Baeat 1:500 or 1:1000 dilution. HSP70 (Cat#. 4876), CD9 (Cat#. 13403), CD81 (Cat#. 56039), EGFR (Cat#. 4267), BAX (Cat#. 5023), and PARP1 (Cat#. 9542) from Cell Signaling Technology (Danvers, MA, USA); and Cytochrome

(3) PRDX1 promotes clear cell renal cell carcinoma progression by modulating EGFR-dependent AKT pathway activationFront PharmacolApril 17, 2026Zhi Liang, Xiaochun Lin, Shen Zeng, Lili Wu, Yujun Dong, Chen Zhang, Mei Li, Fudi Zhu, Lu Chen, Suiqin Niwere treated with 100 ng/mL epidermal growth factor (EGF) (MCE, Shanghai, China) for 30 min. EGFR (4267S, CST), p-EGFR (Tyr1068, 3777S, CST), AKT (4691T,CST), p-AKT (Ser473, 4060L, CST), PI3K (4257T, CST),

(4) PIK3CA mutant cervical cancer is selectively suppressed by PI3Kα inhibition (Alpelisib/BYL-719 and Inavolisib/GDC-0077) and cooperates with HPV directed T cell therapyNeoplasiaApril 13, 2026Hong Lou, David Langan, Nick Syracuse, Elisabeth A. Murphy, Sojung Kim, Emma Robinson, Nicole M. Rossi, Yi Xie, Sonam Tulsyan, Tawnjerae Joe, et al.YAP1, (Cell Signaling Technology Cat# 14074, RRID: AB_2650491), EGFR (Cell Signaling Technology Cat# 4267, RRID: AB_2800085), CTGF (Cell Signaling Technology Cat# 86641, RRID: AB_2800085), Integrin α6 (Cell Signaling Technology

(5) Loss of ZNRF3/RNF43 Unleashes EGFR in CancerElifeApril 10, 2026Fei Yue, Amy T Ku, Payton D Stevens, Megan N Michalski, Weiyu Jiang, Jianghua Tu, Zhongcheng Shi, Yongchao Dou, Yi Wang, Xin-Hua Feng, et al.(Duolink In Situ Red Starter Kit Mouse/Rabbit). The primary antibodies, EGFR (D38B1) XP rabbit antibody (Cell Signaling Technology, 4267) and Myc-tag (9B11) mouse antibody (Cell Signaling Technology, 2276), were used to detect ZNRF3 and

(6) Kasugamycin Inhibits Melanoma Lung Metastasis and CHI3L1-Driven M2-Like Tumor-Associated Macrophage DifferentiationImmunotargets TherMarch 19, 2026Takayuki Sadanaga, Han-Seok Jeong, Roberto Cortez, Joyce H Lee, Suchitra Kamle, Bing Ma, Sung Jae Shin, Jack A Elias, Chun Geun LeeCell Signaling Technology), phosphorylated EGFR (Tyr1068) (p-EGFR) (#44-788G, Thermo Fisher Scientific), EGFR (D38B1, #4267S, Cell Signaling Technology), phosphorylated Erk (p-Erk) (#9101S, Cell Signaling Technology), total Erk

(7) The Galectin-3-binding protein promotes angiogenesis in pancreatic cancer via simultaneous upregulation of VEGFA and direct HUVEC activation mediated by and VAMP5-STAT3Cell Communication and SignalingMarch 18, 2026Ye Jin Lim, Dong Woo Son, Eun Ji Lee, Chae Won Yu, Yun Ok Oh, Min Jung Cha, Hyori Kim, Kyunggon Kim, Suhwan Changantibody (ab46154, Abcam), anti-p-EGFR antibody (3777, Cell Signaling Technology), anti-EGFR antibody (4267, Cell Signaling Technology), anti-p-AKT antibody (9271, Cell Signaling Technology), anti-AKT antibody

(8) Surface-engineered dual drug-loaded tumor-targeted liposomal nanoparticles to overcome the therapeutic resistance in glioblastoma multiformeCommun Med (Lond)March 18, 2026Ramcharan Singh Angom, Hari Krishnareddy Rachamala, Naga Malleswara Rao Nakka, Vijay Sagar Madamsetty, Paola Suarez-Meade, Beatriz I. Fernandez-Gil, Tanmay Kulkarni, Raegan M. Weil, Shamit Dutta, Enfeng Wang, et al.(Anti-N-Cadherin, #4061), Anti-mTOR #2972), phospho-mTOR (Rabbit mAb #5536), Anti-EGFR (Rabbit mAb #4267), and Anti-ATM (Rabbit mAb #2873), were obtained from Cell Signaling Technology. Anti-ATR (sc-515173),

(9) Aptamer-functionalized exosomes combined with doxorubicin suppress GBM progression and enhance chemoradiosensitivity by promoting pyroptosisMater Today BioMarch 9, 2026Jing Wang, Li Peng, Xinxin Zhong, Siqi Zheng, Xiuhua Liang, Menghan Du, Xiangning Xia, Ting Guo, Lidan Zheng, Yingying Fang, et al.4937, 1:500), anti-pATM (Ser1981) (CST, 5883, 1:500), anti-ATM (CST, 2873, 1:1000), anti-EGFR (CST, 4267, 1:1000), anti-pEGFR (tyr1038) (CST, 3777, 1:1000), anti-pChk2 (T68) (CST, 2661, 1:500), anti-Chk2 (CST,

(10) Investigating PAK inhibition in combination with PD-1 blockade to enhance cytotoxic CD8+ T cell-mediated killing and suppress invasion of ovarian cancer cellsBritish Journal of CancerMarch 6, 2026Alexandria R. Mitchell, Yiran Chen, Giuseppe Pugliese, Gabriela Vino Flores, David M. Davies, John Maher, Claire M. Wells,Cell Signaling,2602S,Rabbit,1:1000 PAK2,Cell Signaling,2608S,Rabbit,1:1000 PAK4,Cell Signaling,62690S,Rabbit,1:2000 EGFR,Cell Signaling,4267S,Rabbit,1:1000 "PD-L1, clone 5H1",Millipore,MAB1115,Mouse,1:1000 PAK3,Cell Signaling,2609S,Rabbit,1:1000 PAK5

(11) An MIEN1-based hexamer peptide (LA3IK) inhibits EGF-driven oncogenic signaling in prostate cancer by disrupting EGFR–ERBB2 heterodimerizationScientific ReportsMarch 5, 2026Amit K. Tripathi, Nafees Ahamad, Antariksh Tyagi, Benedicta Quainoo, Adam W. Smith, Pragati Singh, Nirupama Sabnis, Jamboor K. VishwanathaY1173 Rabbit mAb (Cat# 4407), phospho-EGFR Y992 Rabbit mAb, (Cat# 2235), and total EGFR Rabbit mAb(Cat# 4267), all obtained from Cell Signaling Technology and used at a 1:1000 dilution. Additional antibodies from

(12) SMK-002 inhibits the growth of bladder cancer cells and increases their sensitivity to Osimertinib via enhancing epidermal growth factor receptor degradationThe Korean Journal of Physiology & PharmacologyMarch 1, 2026Xiaochen Zhou#, Yizhi Bu#, Di Xiao, Duo Li, Xiaoping Yang550 nm. Data were normalized to the vehicle control. Western blot The antibodies used were EGFR (4267S, CST), p-EGFR (3777T, CST), p-c-Raf (9421T, CST), p-ERK (4370S, CST), Ub (Sc8017, Santa), USP11 (ab247005,

(13) ROR1-PI3K/AKT signaling drives adaptive resistance to cell cycle blockade in TP53 mutated ovarian cancerCell Death & DiseaseFebruary 27, 2026Juuli Raivola, Frida Rantanen, Alice Dini, Emilia Piki, Harlan Barker, Elina Multamäki, Franziska Bentz, Pia Sunkel, Aino-Maija Kiiski, Lassi Paavolainen, et al.STAT1 (#65917, CST), STAT1-pTyr701 (#88845, CST), PTK7 (#25618, CST), ROR1 (#16540, CST, 1:500), EGFR (#4267, CST), WEE1 (#13084, CST). 10 µg of protein was loaded in all the immunoblots. Secondary antibodies

(14) B7-H3-mediated cis-inhibition of EGFR by a tumor-selective bispecific antibody enhances anti-tumor efficacy and minimizes toxicitiesNature CommunicationsFebruary 24, 2026Jian Guan, Tiongsun Chia, Bin Li, Tianyu Zhu, Zhengguang Liao, Junjie Deng, Fenggen Fu, Weiwei Wu, Chengtao Liu, Ya Liu, et al.immunofluorescence (mIF), and western blotting (WB), the following antibodies were utilized: EGFR (CST, 4267), pEGFR (CST, 3777), B7-H3 (CST, 14508), AKT (CST, 4691), pAKT (CST, 4060), ERK (CST, 4695), pERK (CST,

(15) Pan-cancer N-glycoproteomic atlas of patient-derived xenografts uncovers FAT2 as an actionable surface targetCell Reports MedicineFebruary 17, 2026Meinusha Govindarajan, Salvador Mejia-Guerrero, Shawn C. Chafe, Shahbaz Khan, Wei Shi, Matthew Waas, Martin A. Rossotti, Amanda Khoo, Lydia Y. Liu, Vladimir Ignatchenko, et al.,Cell Signaling Technology,Cat# 6943; RRID:AB_10013641 EGFR (D38B1) Rabbit monoclonal antibody,Cell Signaling Technology,Cat# 4267; RRID:AB_2246311 Anti-Human EGFR antibody,R&D systems,Cat# FAB9577B; RRID:AB_2942016 PE-Cy™7 Mouse Anti-Human CD3

(16) A human patient-derived organoid biobank to model tumor heterogeneity and therapeutic vulnerability for oral squamous cell carcinomaCell Reports MedicineFebruary 17, 2026Yuhan Wang, Pengfei Diao, Pin Lv, Na Qi, Ziyu Wang, Enshi Yan, Jin Li, Yanling Wang, Dongmiao Wang, Yaping Wu, et al.AB_3073806 Anti-SOX2,Cell Signaling Technology,Cat#3579; RRID: AB_2195767 Anti-EGFR,Cell Signaling Technology,Cat#4267; RRID: AB_2246311 Anti-Ki67,Proteintech,Cat#27309-1-AP; RRID: AB_2756525 Anti-KRT5/6,Proteintech,Cat#68295-1-Ig;

(17) Therapeutic synergies that overcome carboplatin resistance in triple-negative breast cancerJournal of Experimental & Clinical Cancer ResearchFebruary 3, 2026Julia E. Altman, Aaron Valentine, Nina Dashti-Gibson, Emily K. Zboril, David C. Boyd, Rachel K. Myrick, Amy L. Olex, Mikhail G. Dozmorov, J. Chuck HarrellR",,1:500,Novus,#NBP1-84726 TYMP,IgG,H,,1:500,ProteinTech,#12383-1-AP ANPEP,IgG,"H, M, R",,1:500,ProteinTech,#14553-1-AP EGFR,IgG,"H, M, Mk",,1:50,Cell Signaling Technology,#4267 Primary antibodies used for IHC staining

(18) Mosaic partial epidermal reprogramming remodels neighbors and niches to refine skin homeostasis and repairNature CommunicationsJanuary 30, 2026Minjun Kwak, Eunjun Choi, Yemin Jo, Boa Kim, Chaeryeong Lim, Jooyoung Lim, Yoon Ha Choi, Jung Hyun Lee, Kee-Pyo Kim, Bon-Kyoung Koo, et al.antibodies were used in this study at the indicated dilutions: rabbit anti-EGFR (Cell Signaling Technology, 4267S, 1:1000), rabbit anti-phospho-EGFR (Cell Signaling Technology, 3777S, 1:1000), rabbit anti-AKT (Cell Signaling Technology

(19) Transient proliferation by reversible YAP and mitogen control of the cyclin D1/p27 ratioCommunications BiologyJanuary 29, 2026Katherine R. Ferrick, Samsara W. Upadhya, Yilin Fan, Nalin Ratnayeke, Mary N. Teruel, Tobias MeyerCell Signaling Technology Cat# 8661, RRID:AB_11217435), rabbit anti-EGFR (1:1000, Cell Signaling Technology Cat# 4267, RRID:AB_2246311), rabbit anti-GAPDH (1:1000, Cell Signaling Technology Cat# 5174, RRID:AB_10622025),

(20) A Three-subtype Molecular model of Cervical Cancer: Multiple PI3K Pathway inhibitors suppress growth and cooperate with HPV-directed immunotherapymedRxivJanuary 28, 2026Hong Lou, David Langan, Nick Syracuse, Elizabeth A. Murphy, Sojung Kim, Emma Robinson, Nicole M. Rossi, Yi Xie, Sonam Tulsyan, Tawnjerae Joe, et al.YAP1, (Cell Signaling Technology Cat# 14074, RRID: AB_2650491), EGFR (Cell Signaling Technology Cat# 4267, RRID: AB_2800085), CTGF (Cell Signaling Technology Cat# 86641, RRID: AB_2800085), Integrin α6 (Cell Signaling Technology

Write a Review

(1)

2/8/2019Very Good EGFR AntibodyDr. Sandip ChavanThis antibody was selected as part of the ImmunoOncology project where we performed western blot and IHC for EGFR on Human Lung Cancer Tissues. The antibody is very specific and the results were in ... Read Review
(1)

10/7/2015Immunocytochemistry of EGFR Lakshmi Reddy BolluWe were testing this antibody to stain EGFR on cancer cells through immunocytocytochemistry.

EGF Receptor (D38B1) XP ® Rabbit mAb

EGF Receptor (D38B1) XP ® Rabbit mAb from Cell Signaling Technology

Questions and Answers

Cell Signaling Technology

Citations (1170)

Reviews

EGF Receptor (D38B1) XP ® Rabbit mAb from Cell Signaling Technology

About Biocompare

Advertise with Us

Specialized Search Tools

Site Map